Search

for
Search:

Research

5 / 322 results

Diphencyprone and Topical Tacrolimus as Two Topical Immunotherapeutic Modalities: Are They Effective in the Treatment of Alopecia Areata Among Egyptian Patients? A Study Using CD4, CD8, and MHC II as Markers

research Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers

13 citations , June 2010 in “Journal of dermatological treatment”

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

research 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse

1 citations , November 2023 in “Journal of Investigative Dermatology”

Farudodstat may effectively treat alopecia areata without harming hair follicles.

research LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment

1 citations , August 2023 in “Journal of Investigative Dermatology”

Farudodstat may help treat alopecia areata by protecting hair follicles.

research ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment

May 2023

Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.

research In vitro analyses of CD4-protein function in dedifferentiated keratinocyte cell lines

January 2023

The CD4 protein may play a role in the behavior of certain skin cells, affecting their growth, movement, and differentiation.

View more "mhcii treatment" in research →

Community Join

3 / 1000+ results

community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

in Research/Science 110 upvotes 2 years ago

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

community Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies

in Research/Science 14 upvotes 2 years ago

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

community Prolactin's role in antitumor activity of the immune system - a safety concern for HMI-115?

in Research/Science 4 upvotes 3 years ago

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

View more "mhcii treatment" in community →

Clinics

6 / 169 results

All 169 clinic results →

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →